Bladder cancer

Gwynn, Eric S; Clark, Peter E.

doi:10.1097/01.cco.0000219258.75961.1a

Cited by 13 publications

(8 citation statements)

References 67 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The goal of all these approaches was to improve the penetration and accumulation of drugs in bladder tissues [10][11][12][13]. Intravesical thermo-chemotherapy with mitomycin C (MCC) represents one of the most deeply studied strategies.…”

Section: Introductionmentioning

confidence: 99%

Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients

Milla

Fiorito

Soria

et al. 2014

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

3ABSTRACT Purpose To evaluate, for the first time, the mitomycin C (MMC) pharmacokinetics during intravesical hyperthermia treatment based on conductive heat and the stability and recovery of the drug at the end of the instillation period. MethodsEleven patients with recurrent intermediate risk superficial transitional cell carcinoma of the bladder were treated weekly for 6 cycles with intravesical MMC (40 mg MMC in 50 ml) in local hyperthermia (45°C) with Unithermia ® system. Each instillation lasted 45 min, with the solution being replaced after the first 22 min. The MMC recovery at the end of the two instillation period and the plasmatic pharmacokinetics of MMC were evaluated by high-pressure liquid chromatography (HPLC). ResultsNine patients completed all the 6 planned cycles, whereas 2 patients missed the last cycle because of allergic reactions No other systemic toxicity was observed, the local toxicities were mild. Median MMC concentration in the instillation residual solution decrease from the initial 0.8 mg/ml to 0.22 mg/ml for the 0-22 min instillation period and to 0.38 mg/ml for the 22-45 min instillation period; the median % of MMC recovered after instillation was 66.2 and 99.6, respectively. In all patients MMC plasmatic C max resulted considerably lower than the toxic threshold (400 ng/ml). ConclusionsThe MMC is stable during the instillation and its absorption occurs mainly during the first minutes of the treatment. The plasmatic MMC concentration is always well below the threshold level for myelosuppression, as confirmed by the total lack of hematological toxicity evidenced by the patients. In order to evaluate the efficacy of the treatment performed with UniThermia ® in reducing the disease recurrence rate in short-and long-term follow-up, we are currently carrying out a clinical multicentric study involving a larger number of patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients

Milla

Fiorito

Soria

et al. 2014

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Despite these measures, about 5% to 20% of non-muscle-invasive tumors will progress to muscle-invasive disease. High-grade non-muscle-invasive tumors are related to a high risk of muscular invasion and metastasis and end up with a worse prognosis [5]. Also, it is known that metastasis can appear without muscular invasion; these metastases are found in regional lymph nodes during cystectomy [5].…”

Section: Discussionmentioning

confidence: 99%

Metastasis of Non-Muscle-Invasive Bladder Cancer Into the Thyroid Gland: A Literature Review Accompanied by a Rare Case

et al. 2014

View full text Add to dashboard Cite

Bladder cancer is the most prevalent malignancy of the urinary tract. About 90% of bladder cancers are urothelial carcinomas. Seventy percent of cases newly diagnosed are superficial diseases; roughly 30% of newly diagnosed cases are muscle-invasive metastatic diseases. Bladder urothelial carcinoma primarily metastasizes into regional lymph nodes and then into liver, lung, mediastinum, bone, and adrenal gland. In our case, non-muscle-invasive bladder cancer metastasized into the bone, mediastinum, iliac lymph node, and adrenal and thyroid glands. This is the first reported case in the current literature in which urothelial carcinoma metastasized into the thyroid gland.

show abstract

“…In addition to this reason, increased internal pressure of the bladder greater than surrounding venous pressure after TURBT due to fluid infusion during procedure and high histologic grade of the tumor are associated with extravesical metastasis after TURBT (4,5). Here we describe a case of extravesical metastasis occurring after repeated TURBT of non-invasive bladder cancer.…”

Section: Introductionmentioning

confidence: 91%

A Case of Extravesical Metastases Occurring after Transurethral Resection of Non-Invasive Bladder Cancer

Kang

Sohn

Chung

2018

J Korean Soc Radiol

View full text Add to dashboard Cite

show abstract

Bladder cancer

Cited by 13 publications

References 67 publications

Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients

Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with Mitomycin C in superficial transitional cell carcinoma patients

Metastasis of Non-Muscle-Invasive Bladder Cancer Into the Thyroid Gland: A Literature Review Accompanied by a Rare Case

A Case of Extravesical Metastases Occurring after Transurethral Resection of Non-Invasive Bladder Cancer

Contact Info

Product

Resources

About